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ABSTRACT
Objective: To provide guidance for the use of the main functions available in R for performing post hoc Bayesian analysis of a
randomized clinical trial with a survival endpoint using proportional hazard models.
Study Design and Setting: Data derived from the ALLOZITHRO trial, conducted with 465 patients after allograft to prevent
pulmonary complications and allocated between azithromycin and placebo; airflow decline–free survival at 2 years after
randomization was the main endpoint.
Results: Despite heterogeneity in modeling assumptions, in particular for the baseline hazard (parametric or nonparametric),
and in estimation methods, Bayesian posterior mean hazard ratio (HR) estimates of azithromycin effect were close to those
obtained by the maximum likelihood approach.
Conclusion: Bayesian models can be implemented using various R packages, providing results in close agreement with the
maximum likelihood estimates. These models provide probabilistic statements that could not be obtained otherwise.
Date: 18 August 2019
1 Introduction
Bayesian approaches for clinical trials have received considerable interest in recent decades as a complementary tool to enhance
the interpretation of clinical trials1. It has recently been highlighted2, 3 that in the clinical trial setting, Bayesian analyses appear
as a complementary tool for clinicians, patients, and policymakers. However, Bayesian analysis of clinical trials is mostly
restricted to the (often uncontrolled) phase II setting4 or phase III randomized clinical trials (RCTs) with a binary outcome
measure5. In the case of right-censored endpoints, a number of methods have been proposed for the Bayesian analysis of trial
data by considering failure at a specific point in time and treating the data as binary. Indeed, compared to the straightforward
beta-binomial framework for a binary variable, the use of Bayesian inference appears difficult to apply. This is notably true
when the primary outcome is a survival outcome, and although several papers and a book6 have been dedicated to Bayesian
survival analyses, such methods are still underutilized in the clinical literature of RCTs7.
In such a comparative evaluation of survival, interest generally lies in the hazard ratios, which are classically estimated
using the popular Cox regression analyses provided within standard statistical packages. We thus focused our interest on the
Cox proportional hazards (PH) model, and considered how, and with what functions from standard software, to implement a
Bayesian estimation of the hazard ratio (HR) as the measure of the treatment benefit in an RCT.
Although many R packages are available for implementing survival models to handle right-censored data, only a few
packages provide Bayesian estimation of those approaches. Moreover, all those packages differ in the modeling choice of the
baseline survival, which complicates their comparison in practice. First, two main choices of modeling are considered, either
fully parametric – with survival times drawn from any parametric (exponential, piecewise constant hazard, etc.) family – or
semi-parametric, with various nonparametric estimators of the survival functions. Second, these packages consider various
modeling options for the prior density of the model parameters, including the regression coefficient measuring the randomization
effect, and the additional baseline survival distribution that may include hyperparameters. Third, although model parameter
estimation and statistical inference are mostly (though not consistently) conducted via self-tuning adaptive Markov chain
Monte Carlo (MCMC) methods, the techniques may differ with respect to computational samplers, including starting values,
algorithms and convergence diagnostics. Fourth, those packages are not easy to use in terms of defining all the parameters and
priors. To improve the use and reporting of Bayesian analysis in survival trials as recommended8, additional effort should be
made to allow the appropriation of such methods by nonspecialized teams.
Therefore, the aim of this paper is to present and apply these different Bayesian parameterizations for PH survival models
when analyzing data derived from an RCT with a survival outcome as the endpoint of interest. We also wish to assess whether
those various estimates are relatively robust in terms of model conclusions for clinicians, patients, and policymakers. As an
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illustrative example, we use data from the ALLOZITHRO clinical trial (NCT01959100), that randomized 465 patients between
azithromycin (234 patients) and placebo (231 patients) from February 2014 to August 2015, to prevent airflow decline after
allogeneic stem cell transplantation for malignancy9. This is a post hoc Bayesian analysis of the main endpoint of the trial,
airflow decline–free survival. For confidentiality reasons, we could not provide the original trial dataset; however, we used a
resampled mock dataset that is similar to the data presented in the manuscript.
For each of the reviewed PH models, we provide the results of their implementation using functions directly from R
packages and data from the ALLOZITHRO example.
2 Bayesian models for survival data
Let N be the number of patients in the study, let X1, . . . ,XN , denote the right-censored time, and let Z1, . . . ,ZN denote
a randomized group of individuals. In this paper, we consider the Cox proportional hazards model. Data are given by
(X1,Z1), . . . ,(XN ,ZN), where :
Xi|Zi ∼ F(t|Zi) = 1− (1−F0(t))exp(Z′iβ ), i = 1, . . . ,N (1)
Or, equivalently,
H(t|Zi) = exp(Z′iβ )H0(t) (2)
where F0(t) = 1− S0(t) is the baseline distribution function of the right-censored time and H(t|Z) =
∫
h(u|Z)du is the
cumulative hazard function of the patients whose covariate is Z and instantaneous hazard is h0(t).
2.1 Partial Bayesian approach
In a RCT, given the main interest lies in the treatment effect, Bayesian inference frequently ignores the baseline hazard10. This
process results in modeling only the treatment effect size, which is measured by the log hazard ratio β = log(HR), considered
to be normally distributed10.
The normal prior for β is expressed asN (µ,σ20 ), with σ
2
0 = 4/n0 asymptotically, where n0 is the "implicit" sample size
of the prior information given by the effective number of events10–12. This value is usually computed using the Schoenfeld
formula as n0 =
(z1−β+z1−α/2)2
p2µ2 , where α is the type I error rate, β is the type II error rate, z1−x is the (1− x) quantile of the
standard normal distribution, and p = 1/2 is the proportion of patients allocated to each arm (balanced RCT).
Given the normality of the likelihood estimate y of the log(HR) on the data, with a sampling distribution y∼N (β ,σ2),
where σ2 is the variance of the estimate, the computation of the posterior distribution is direct. Indeed, the application of Bayes’
theorem gives the following posterior distribution:
β |y∼N
[
µσ2+ yσ20
σ2+σ20
,
σ2σ20
σ2+σ20
]
.
The method first requires the specification of a mean prior for β , the log(HR); according to Spiegelhalter e al.12, two priors,
a skeptical prior centered on the null hypothesis (that is, µ = 0) and an enthusiastic prior centered on the alternative hypothesis,
are recommended. Then, the posterior mean of β |y is directly computed without the need for any specific function from the R
package. The pnorm() and pqnorm() functions in R enable the posterior probabilities of specific intervals of log(HR) values
and credibility intervals of the estimates, respectively, to be computed.
2.2 Fully Bayesian approaches
By contrast, in a fully Bayesian approach, the model in equation (1) has two parameters, namely, β and F0, that require
specification of priors. Although the specification of baseline survival can equivalently use the survival function (S0) or hazard
functions (H0 or h0), Bayesian inference methods differ in this component of the model, which is considered as either drawn
from a parametric distribution or not. We will see that defining priors on such different quantities may yield differences in
estimates.
Unfortunately, such models are not analytically tractable, and inference about parameters or quantities of interest requires
approximate integration, such as Laplace’s method, or an approximate technique, such as MCMC. In MCMC, samples can be
generated from a posterior density and used to approximate expectations of the quantities of interest. These methods were
first implemented in specific statistical software. Following WinBUGS in 199713, JAGS14 and Stan15 were developed to
achieve this aim and can be freely downloaded. Recently developed r2jags and rstan R packages provide an interface
for their use with R. Additionally, the INLA package implements integrated nested Laplace approximations for Bayesian
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inference as an alternative approach to MCMC16. Moreover, in the setting of Bayesian survival, several R libraries have
been developed to address specific statistical aspects: for instance, dynsurv focuses on Cox models with time-varying or
dynamic covariate coefficients for interval-censored and right-censored survival data17, spBayesSurv addresses spatial
survival data18, survHE19 proposes survival models for health economics studies, rstanarm constructs regression models
using Stan including a joint survival model, and SemiCompRisks estimates hierarchical multistate models for the analysis of
independent or clustered semicompeting risks data20.
Most of these models consider a normal prior for log(HR):
β ∼N (µ0,σ20 ).
Flat priors are commonly set as default in these packages, with mean µ0 = 0 and varying standard deviation σ0, for instance,
from 1 in the dynsurv package up to 1010 in the spBayesSurv package18.
The packages differ mostly in modeling the baseline survival function. Their main differences are detailed below and
summarized in Table 1.
2.2.1 Parametric PH models
Exponential and Weibull models - The simplest way to provide Bayesian inference in a survival model is to assume the time
to event is drawn from a parametric distribution. The models have the same multiplicative structure as the Cox PH model,
but rather than leaving the baseline hazard unspecified, it is assumed to be a power transform of the time scale. This model
formulation allows for the fact that the baseline hazard over time may be constant (exponential distribution), increasing or
decreasing (Weibull distribution). The use of a parametric baseline survival results in a fully parametric PH model. This method
was used for empirical Bayesian analysis by Kalbfleish21, with the conclusion of avoiding the assessment of data by using only
one parametric survival model22.
The likelihood for such models can be shown to have the following form
L(θ ,β ) =
n
∏
i=1
(
h0(t|θ)eβT Zi
)δi
exp
[
−
∫ ti
0
h0(u|θ)eβT Zidu
]
where h0(t|θ) is the baseline hazard function, dependent on a vector of unknown parameters θ , δi is an indicator of failure for
the ith patient, taking a value of one if the ith patient experienced failure and zero otherwise, and ti is the time of failure or
censoring time for the ith patient.
Bayesian inference incorporates prior information expressed as a probability density function on so-called hyperparameter(s)
θ of the survival distribution, that requires estimation23. The priors for the hyperparameters are commonly based on log-normal
or gamma distributions. The prior information on θ and β can then be combined with the observed data likelihood described
above, using Bayes’ theorem, to obtain a posterior density function.
Such models are not analytically tractable, and inference about the parameters of interest requires approximation methods
or MCMC, implemented using BUGS, JAGS or Stan, for instance. Recently, R packages specifically dedicated to survival
data have been developed7, 24. Thus, models are currently readily available in the SemiCompRisks package (function
BayesSurv_HReg(, model="Weibull"))20, in the INLA package16, in the rstanarm package (function stan_surv() with
argument basehaz="exp" or basehaz="weibull"), and in the survHE package (which allows inference through either INLA
via a call to the INLA package or Hamiltonian Monte Carlo simulation (HMC) via a call to rstan)19.
Piecewise exponential models - To allow the baseline hazard to be more flexible, a piecewise exponential model, sometimes
referred to as piecewise constant model, has been proposed, where the hazard changes from time to time during the observation
period but remains constant within each time interval. This model thus requires the definition of a partition of M intervals
Ik = (dk−1,dk],k = 1, . . . ,M,d0 = 0 and dM = ∞, where the baseline hazard is constant and equal to an unknown value, hk > 0:
h0(t) = ∑Mk=1 hkI{t ∈ Ik}. The parameters of interest are then hk, which are associated with priors, usually from gamma
distributions.
In the most basic form, a piecewise constant hazard model can be obtained via the so-called "Poisson trick". Provided
a reformatting of the time-to-event data aggregated by time intervals (number of events and total patient-time available for
each time interval), a Poisson regression model is used to estimate the treatment effect and K independent piecewise constant
hazards hk. A dependence among piecewise hazards may also be defined in dedicated models.
PEM models are for instance implemented in the indeptCoxph() function of the R spBayesSurv package18, where dk is
set as the km th quantile of the empirical distribution of the observed survival times for k = 1, . . . ,M−1:
hk ∼ Γ(r0h,r0)
with hk assumed to be independent, and the default hyperparameter values are set to M = 10,r0 = 1,h = hˆ, the maximum
likelihood estimate of the rate in an exponential PH model. Another implementation is available in the SemiCompRisks
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package, with the function BayesSurv_HReg(), with the interval partition sampled from a time-homogeneous Poisson process
prior (with multinormal prior on the piecewise log-hazards, centered on zero and Gamma hyperprior, Γ(a,b), on the variance
terms, a Poisson prior on the number of intervals M, with hyperparameter α to be specified by the user). Similarly, in the INLA
package, PEM can be estimated with log(h0(t)) modeled over M intervals with a random walk process of order 1 or 2 on the
difference log(hk)− log(hk−1).
2.2.2 Nonparametric priors
A variety of Bayesian nonparametric priors have been applied to baseline survival distributions S0(t), which is straightforward
since each PH model has a simple formula that relates survival to covariate information through this baseline and a linear
function of the covariates. Those priors proposed in R packages are briefly described below.
Polya tree priors
Fully Bayesian semiparametric survival models based on MCMC methods were developed by Walker et al.25 using Polya tree
priors. More recently, mixtures of Polya tree (MPT) priors were also developed, in the setting of spatial frailty modelling26–28.
These methods are implemented in the function survregbayes2() of the R spBayesSurv package18, which notably allows for
PH models without frailty (in case of non spatial data). Options for the centering distribution for the MPT prior include Weibull
distribution, log-logistic and log-normal distributions (see table 1).
Transformed Bernstein polynomial
The transformed Bernstein polynomial (TBP) prior has also been proposed for fitting the baseline survival function. Unlike the
mixture of Polya trees, the TBP prior selects smooth densities, leading to efficient posterior sampling. Given a fixed positive
integer L, a TBP prior follows:
S0(t) =
L
∑
j=1
w jI(Sθ (t)| j,L− j+1),wL ∼ Dirichlet(α, . . . ,α)
where wL = (w1, . . . ,wL)T are positive weights, I(.|a,b) is the beta cumulative function with parameters (a,b), and Sθ is a
parametric survival function with parameter(s) θ (e.g., log-logistic, Weibull, log-normal). The parameter α controls how close
the shape of S0(t) is relative to the prior guess Sθ : small values of α allow more pronounced deviations of S0(t) from Sθ . Thus,
such Bernstein polynomials enable density estimation on bounded domains, typically by transforming data to lie in the interval
[0,1]. This process provides a convenient way to create a Bayesian nonparametric prior for smooth densities, leading to efficient
posterior sampling. This technique is implemented in the function survregbayes() of the R spBayesSurv package18.
Splines
Piecewise log-hazard with low-rank thin plate (LRTP) splines. Murray et al. proposed a flexible framework using LRTP linear
splines for a continuous log-hazard function, as opposed to the discontinuous hazard in piecewise exponential models described
above29. Of note, this method was developed specifically to handle time-dependent effects of covariates, but the model can be
simplified for the assumption of proportional hazards across treatment groups. R functions are available online, calling JAGS
for MCMC estimation (https://www.counterpointstat.com/software-and-peer-reviewed-literature.html).
Cubic M- and B-splines can be used to model the baseline hazard30. Such models are to be available in a new survival branch
of the rstanarm package, currently under development; for the present work, we used its development version, as available
on Github. In absence of time-dependent effects, the estimation process is faster with M-splines than B-splines given a closed
form for cumulative hazard is available only in this case.
Of note, piecewise spline modeling of the log-hazard is sometimes categorized along with PEMs; there are similarities
in the modelling approach with partitioning of the time axis, although, in the case of splines, the log-hazard is not piecewise
constant contrary to the models described in section 2.2.1.
For the methods using MCMC, the functions and packages also differ in terms of the default simulation parameters (number
of iterations, chains, etc.). A description of the default parameterizations is available in Table S1 in the Supplementary material.
3 Illustrative example derived from the ALLOZITHRO trial
An example dataset was generated from the original ALLOZITHRO trial data: we randomly drew a sample with the same
number of observations, using bootstrap (with replacement), stratified on the randomization arm. At the time of analysis, 231
patients (50%) had experienced a primary event: 129 in the azithromycin group and 102 in the placebo group. There was no
evidence of any significant violation of the proportional hazards assumption, as assessed by the Grambsch and Therneau test
(P = 0.60)31.
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Using a standard data analysis based on maximum likelihood estimation of a semiparametric Cox PH model, the estimated
hazard ratio of airflow decline (AFD)-free survival was HR = 1.44, 95%CI: 1.11 to 1.87 (p-value=0.006) (figure 1).
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Figure 1. Estimated Kaplan-Meier AFD-survival according to randomization
We then applied the Bayesian approaches described above. Estimates of the posterior log(HR) throughout the different
approaches, with their default parameterization (see details in Supplementary material, table S1), are summarized in Figure 2
and Table S2 in Supplementary material.
3.1 Non-fully Bayesian analyses
We first applied the partial likelihood approach and model described in section 2.1. We considered normal priors for log(HR).
As previously done32, the skeptical prior corresponded to the belief that there was no difference between groups, which was
expressed by a prior mean for log(HR): µ = 0, while the enthusiastic prior was set to µ = log(0.64) =−0.45, corresponding
to the postulated expected 15% benefit over the 2 year estimated AFD-free survival of 45% in the control arm, which was used
in the protocol to compute sample size. Other prior parameters were set to n0 = 10 and σ0 = 0.63, using the formulas described
above.
On the basis of the Bayesian partial conjugated normal model, log(HR) was set to y = 0.366 with a standard error of
σ = 0.133. This resulted in a posterior mean log(HR) of 0.351 or 0.332 for the skeptical or enthusiastic prior, respectively
(figure 3, left panel). Compared to the standard HR estimate of 1.44, these Bayesian analyses produced similar mean posterior
skeptical and enthusiastic estimates of HR of 1.42 and 1.39, respectively. Bayesian inference also provided a posterior
probability of HR > 1.5, which was computed for both priors, skeptical and enthusiastic, at 0.34, and 0.29, respectively.
3.2 Fully Bayesian analyses
We then applied parametric and semi-parametric fully Bayesian survival models. MCMC convergence diagnostics are available
in Supplementary material (Figures S1 and S2).
Parametric baseline hazard
We first considered exponential and Weibull models for AFD-free survival, using different packages for comparison purposes,
with their default parametrization for MCMC: SemiCompRisks, INLA, rstanarm, survHE. The default priors on
log(HR) were flat noninformative: uniform with mean zero for SemiCompRisks andN (0,103) for INLA and survHE, or
weakly informative centered on zero for rstanarm, withN (0,2.52). The mean posterior log(HR) ranged from 0.345 to
0.360, which was close to the maximum likelihood estimates for these two parametric models (figure 2).
We then applied piecewise exponential models for the baseline hazard by using the following functions: bayesCox() of the
dynsurv package, indepdtCoxph() of the spBayesSurv package, BayesSurv_HReg() of the SemiCompRisks package
and inla.coxph() of the INLA package. Similarly to the previous models, noninformative flat priors for log(HR) centered on 0
with very large variances resulted in posterior means close to the maximum likelihood estimates in the Cox and parametric
models, suggesting that the prior was swamped with the data. An exception was bayesCox() in dynsurv, which yielded a
log(HR) of 0.260, with 95% credibility interval (-0.042; 0.553).
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Figure 3. Bayesian posterior distribution of the log hazard ratio (log(HR)) - Left panel refers to the non-fully Bayesian
approach with skeptical or enthusiastic priors for log HR. The middle and right panels refer to fully Bayesian semiparametric
PH models, with normal prior for log(HR) and either an exponential distribution, estimated with Stan-Hamiltonian Monte
Carlo approach via the package survHE (middle plot) or a mixture of Polya trees (MPT) prior with centering Weibull
distribution, estimated with the package spBayesSurv model (right plot) for the baseline survival function
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Nonparametric baseline hazard
The results from models with nonparametric estimation of the baseline hazard were consistent whether the prior was defined by
a transformed Bernstein polynomial (TBP) or a mixture of Polya trees (MPT) and regardless of the underlying centering density
family, with the exception of the function provided by Murray et al., with LRTP splines for a piecewise linear log hazard (mean
posterior log(HR)= 0.223)29 and the model with M-splines for the log hazard in rstanarm, with log(HR) = 0.289 (95%CrI
0.041; 0.537) (Figure 2).
Note that the posterior variance was somewhat lower with the partial Bayesian models and the exponential model
implemented in the package survHE with Stan, as illustrated in figure 3.
Sensitivity analyses
Secondarily, we re-estimated the models requiring MCMC using homogenized MCMC parameters for the number of chains
and optimized MCMC convergence (total number of iterations, thinning) (Table S3). Results are available in the Supplementary
material; estimates of the log(HR) were consistent with those in the main analysis and are reported in Table S4, Figure S5.
4 Discussion
Bayesian inference has been proposed as an alternative way for clinicians and policymakers to analyze data from RCTs3.
Indeed, with the development of Markov chain Monte Carlo (MCMC) methods and ever-growing computational capacities, it
has become possible to fit increasingly large classes of models with the aim of exploring the real-world complexities of data.
This could apply to survival models for right-censored endpoints, which are widely used in cancer RCTs. However, only a few
works have been published on Bayesian survival methods. Moreover, they all use various model formulations, various priors,
and integration methods that make their understanding and implementation difficult. We thus aimed to provide a review and
practical guidance for using the main approaches, in open source R software platform.
Except for the bayesCox() function of the dynsurv package and the model proposed by Murray et al29 with LRTP splines
for the piecewise linear baseline hazard function, all posterior mean estimates of azithromycin effect were close on the HR scale
based on either parametric or nonparametric modeling of the baseline hazard or the non-fully Bayesian approach. These results
were obtained using the default parameterizations of the packages, ranging from 1.39 (with the non-fully Bayesian method, with
the enthusiastic prior) up to 1.43 (with the indeptCoxph() function of the spBayesSurv package). Nonparametric estimates
based on transformed Bernstein polynomials or mixture of Polya trees priors for the baseline survival function were between
those estimates. Moreover, the upper Bayesian estimate of 1.43 was close to that obtained by the maximum likelihood (that is,
HR = 1.44).
Estimates of log(HR) were not markedly affected by increasing the variance of the prior (from 1 up to 1010). This results
suggests that some one- or two-parameter baseline survival models should be avoided in this setting.
In all cases, the Bayesian approach further allowed the computation of posterior probability intervals, such as Pr(HR > 1.5),
which cannot be obtained by the standard frequentist approach.
In the piecewise modeling of the time to event functions (either hazard or log-hazard), the choice of partition of the time
domain appears to be crucial. The bayesCox() function of the dynsurv package defines, by default, the time intervals by
the observed failure times in the dataset, with the direct consequence, in our case, of a larger number of intervals and longer
computation time, as advised by the package’s authors for large datasets17. Moreover, the obtained mean log(HR) estimate was
far (HR=1.11) from that of the other methods. A reasonable approach requires enough time intervals M to capture the curvature
of the hazard function17, 29. In the setting of their flexible LRTP spline model of the log-hazard, Murray et al. argues for equally
spaced partitions with a fixed number of M time intervals when conducting simulations and using grid search over M when
analyzing a particular dataset to identify the partition that maximizes the criterion deviance+M29, 33. Quantile-based or equally
spaced partitions are common in the packages we described. When applied to the bayesCox() function, instead of the default
failure times approach, this practice yielded an estimate closer to that of the other methods, and in shorter time (posterior mean
log(HR) =0.4058 [95% CrI: 0.1223 to 0.6919], 0.4004 [95%CrI: 0.1102 to 0.6987] with 5th-percentile partition or 20 equally
spaced intervals on the observed failure times, respectively). Such an impact of the parameterization of the time partition,
resulting in the log(HR) estimate increasing from 0.2604 to 0.4058 in this example, should be emphasized.
Another practical issue that was encountered was the need to rescale the observed failure times for some models to fit. This
requirement is expected for the Weibull model using the INLA package to avoid numerical overflow in the likelihood routine
due to large time values16. For instance, with our dataset, the event times ranged from 0.43 to 24 months; we therefore used the
time expressed in years instead of months to run this model. The same effect was observed with the function of Murray et al29.
In addition to differences in modeling assumptions, the packages also differ in the MCMC default parameterization (number
of iterations, burn-in, number of chains). In some functions, the default number of iterations is small (2000) to avoid lengthy
computations by default when initially assessing functions and models. However, more iterations are likely needed to fit models
and obtain MCMC convergence. Note that computation time was somewhat increased with the dynsurv R package, when
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used with the default time intervals parameterization, as mentioned above. Similarly, some functions run one MCMC chain
only for the posterior distribution estimation. Most functions rely therefore on user expertise to tune the estimation parameters
and conduct diagnostics on MCMC estimation in a given modeling situation. For instance, MCMC mixing for Polya tree
models has been reported to be problematic when the true baseline survival function is very different from the parametric family
that centers the Polya tree and to require particular caution. In our example, this did not appear to be an issue. As with any
statistical inference method, Bayesian model estimation requires a minimum of critical approach, and hands-on or turn-key use
of default functions should be considered with caution to avoid erroneous conclusions. Workflow guidance and tools have been
proposed to that aim34: for instance (not exhaustive), R packages such as boa, coda, bayesplot and shinystan have
been developed to explore MCMC outputs34–36. Overall, the rstan outputs (used in the present analyses via the survHE and
rstanarm packages) were the most comprehensive and straightforward in providing convergence information and diagnostics.
More complex parametric survival models have been implemented in R. For instance, in the context of so-called general
interval-censored data, a mixture of left-, right-, and interval-censored data, Lin et al. used monotone splines to model the
baseline cumulative hazard function37. This approach is available in the ICBayes() function of the R ICBayes package38;
however, this method is not directly applicable to the only right-censored data typically observed in clinical trials. Otherwise, as
proposed by de Iorio et al, the survival function can be modeled nonparametrically by a mixture of Dirichlet processes (DPs)39.
DP mixtures of kernels have been implemented in the function anovaDDP() of the spBayesSurv package, with the choice
of log-normal, log-logistic or Weibull kernels18. More recently, Xu et al proposed a DDP model with a normal kernel, the
DDP-Gaussian Process model (DDP-GP), to model the log-failure time40. This method is implemented in the DDPGPSurv
package41. Morevover, the DDP-GP model allows for individual scaling of included covariates, resulting in greater flexibility
and robustness40. Imprecise or near-ignorance DP are used to estimate the survival function from right-censored data in the
IDPSurvival package, function isurvfit()42. The package provides a test to compare survival functions between groups,
similar to a rank sum test (function isurvdiff()). Note that in these flexible nonparametric modeling approaches, there is
no necessity for resulting survival curve estimates to satisfy the ubiquitous proportional hazards assumption. Nevertheless,
although they estimate the survival distribution according to covariate-defined groups, these approaches do not enable direct
estimation of the average difference between groups, such as the HR.
We considered the proportional hazards setting of the Cox model, as it is the most commonly used survival model for
randomized trials. The PH assumption was not considered violated in our example according to the Grambsch and Therneau
test. Nevertheless, as illustrated in figure 1, some departure from the assumption could be suspected. Nonproportional
hazards models have been proposed in the Bayesian framework and could be of interest in such situations, in particular, in
the development of immunotherapies43. For instance, the package dynsurv has been specifically developed for estimating
time-varying effects of covariates using piecewise models; similarly, the method proposed by Murray et al. includes a model
with a piecewise linear LRTP spline function for a time-varying hazard ratio29. In the setting of joint models for prognostic
studies with biomarkers, the R package rstanarm includes a model with a Weibull distribution for the hazard function and
B-splines for the log hazard (function stan_jm())44–46). Similar models for health economics data were implemented with the R
package survHE, with an underlying parametric baseline hazard function.
Limitations
This study has some limitations. First, we used data derived from the ALLOZITHRO trial as a case study, and results may
be dependent on the dataset. Second, we reported only a few posterior estimates, namely, the posterior mean of the log(HR)
with the 95% credibility interval and the posterior probability of the log(HR) being greater than 1.5, while other probabilistic
statements could have been used to further describe the posterior knowledge on the treatment effect. Indeed, we believe that
providing multiple posterior estimates of the parameter of interest is of prime interest in Bayesian analyses. Third, we focused
on the R software platform to review available functions and libraries. For the rstanarm package, we used the development
version currently available for installation from the survival branch of the package on Github platform, to access the stan_surv()
function. It will be integrated in the next version of rstanarm to be available for standard download. Survival models are
also implemented in other software, such as SAS47, Stata48, and Python with the survivalstan library. Nevertheless, R
statistical software is an open-source platform that allows centralizing various models and estimation algorithms (JAGS, Stan,
custom functions), conveniently enabling the comparison of methods from the same console.
Conclusion
In summary, we follow the statement that ’all models are wrong, but some are useful’, the aphorism generally attributed to the
statistician George Box. When applied to survival analysis, we showed that Bayesian models could be implemented using R
packages, providing results generally in agreement with the likelihood estimates. The non-fully Bayesian approach with a
conjugate Gaussian model on the log(HR) appears to be a reliable and straightforward method to obtain Bayesian estimates for
survival data, provided a proportional hazard setting. In such situations, the main usefulness of the Bayesian approaches may
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be enabling probabilistic statements that could not be obtained otherwise. Therefore, Bayesian approaches should be used more
often.
Computational details
The results in this paper were obtained using R 3.5.3 (distributed under the terms of the GNU General public License
Version 2 or 3), with the following packages: survival 2.43-3, spBayesSurv 1.1.3, coda 0.19.2, bayesplot 1.7.0,
INLA 18.07.12, survHE 1.0.65, SemiCompRisks 3.3, dynsurv 0.3-6, rstantools 1.5.1, rstan 2.18.2, rjags 4-8.
R itself and packages used are available from the Comprehensive R Archive Network (CRAN) at https://CRAN.R-project.org/,
except for the INLA package, which can be installed directly from the R-INLA project website (install.packages("INLA",
repos=c(getOption("repos"), INLA="https://inla.r-inla-download.org/R/stable"), dep=TRUE)) and the rstanarm package,
whose development version including the stan_surv() function used for the reported analyses, can be downloaded and installed
from Github (As of 22 July 2019, devtools::install_github("stan-dev/rstanarm", ref = "feature/survival", build _vignettes =
FALSE)).
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5 Supplementary data
5.1 Default MCMC parameterizations
We initially applied the available R packages and functions using their respective default parameterizations.
Table 2 reports the default parameters for Markov chain Monte Carlo (MCMC) simulations for the functions (total number
of iterations, number of iterations for the burn-in sequence, thinning value, number of chains).
The approach of Spiegelhalter et al. (1994) and INLA estimation rely on other methods for estimation (conjugate Gaussian
prior and integrated nested Laplace approximation, respectively) and are therefore not included in this table.
Table 2. Monte Carlo simulation default parameterizations in the R packages for Bayesian survival PH models
Number of iterations
Package/Method Total Burn-in Thin No. of chains Comment
SemiCompRisks package
BayesSurv_HReg() 2000 1000 10 2 Model output reports posterior
median estimates (not mean)
survHE package
fit.models(...,method="hmc") 2000 1000 1 2
dynsurv package
bayesCox() 3000 500 1 1 MCMC output includes all
iterations (burn-in included
and before thinning)
rstanarm package?
stan_surv() 2000 1000 1 4
spBayesSurv package
indeptCoxph() 5000 3000 1 1
survregbayes() 5000 3000 1 1
survregbayes2() 5000 3000 1 1
Murray et al (2016)
12000 2000 1 2
? As of 22 July 2019, rstanarm development version, including the stan_surv() function, downloaded from the survival branch of the package available
on github at https://github.com/stan-dev/rstanarm/tree/feature/survival
5.2 Numerical example
5.2.1 Estimates with default parameterizations
Table 3 presents the estimates of the log hazard ratio (HR) of event (death or airflow decline) in the azithromycin group over
placebo according to the method on data derived from the ALLOZITHRO trial dataset, obtained with the different methods:
conventional frequentist methods and the Bayesian survival PH models. Functions for Bayesian inference were first applied
with their respective default parameterization, reported in table 3.
Figure 4 and 5 illustrate basic convergence diagnostics on models fitted using MCMC simulations, with default paramteriza-
tions of the respective functions. Each line of the figures corresponds to one function: from left to right, traceplot of log(HR)
posterior draw by iteration per chain, estimated posterior density of log(HR) per chain, potential scale reduction factor (PSRF)
or Rˆ across chains (computed when multiple MCMC chains), effective sample size to number of saved iterations ratio (Ne f f /N)
over all chains. Diagnostics and plots were obtained using coda and bayesplot packages. For homogeneity purposes, we
applied the same diagnostics tools across all functions, and in particular Rˆ and Ne f f /N ratio were computed using the functions
effectiveSize() and gelman.diag() in coda, although specific estimates are directly available in the output of models fitted with
HMC/Stan (obtained here via the survHE package). Similarly, specific tools are available for models estimated via HMC
simulations (Stan).
Functions in the SpBayesSurv package runs only one MCMC chain by default; Rˆ could not be computed (Figure 5).
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Table 3. ALLOZITHRO Trial: Estimates of the log hazard ratio (HR) of event (death or airflow decline) in the azithromycin
group over placebo according to the method. 95%CI refers to the confidence interval for frequentist estimates and to credible
intervals for the Bayesian models. Bayesian models were estimated with the default parameterization of the respective
functions. The probability of a hazard ratio greater than 1.5 can be computed only using Bayesian analyses. PEM: piecewise
exponential model; RW: random walk; TBP: transformed Bernstein polynomial; MPT: mixture of Polya trees
Estimation method Posterior logHR
Mean 95% CI Pr(HR > 1.5)
Frequentist approach
Semiparametric Cox 0.3661 0.1056 to 0.6265 -
Parametric exponential 0.3493 0.0896 to 0.6090 -
Parametric Weibull 0.3389 0.0886 to 0.5893 -
Bayesian models
Spiegelhalter et al. (1994)
Skeptical prior 0.3506 0.0957 to 0.6055 0.3366
Enthusiastic prior 0.3317 0.0769 to 0.5866 0.2854
SemiCompRisks package
Parametric Weibull 0.3507 0.0773 to 0.6082 0.3750
PEM 0.3454 0.1623 to 0.5700 0.3100
INLA package
Parametric exponential 0.3491 0.0900 to 0.6102 0.3346
Parametric Weibull 0.3531 0.0937 to 0.6144 0.3456
PEM RW1 0.3479 0.0883 to 0.6094 0.3317
PEM RW2 0.3481 0.0885 to 0.6096 0.3322
Stan via survHE package
Parametric exponential 0.3549 0.0968 to 0.6148 0.3465
Parametric Weibull 0.3510 0.0992 to 0.6070 0.3315
Stan via rstanarm package?
Parametric exponential 0.3446 0.0810 to 0.6032 0.3275
Parametric Weibull 0.3599 0.1104 to 0.6065 0.3525
M-splines 0.2890 0.0405 to 0.5366 0.1905
B-splines 0.3599 0.1041 to 0.6175 0.3605
dynsurv package
PEM Gamma 0.2604 -0.0415 to 0.5531 0.1720
spBayesSurv package
PEM indeptCoxph() 0.3608 0.1163 to 0.6300 0.3660
TBP survregbayes()
Weibull 0.3373 0.0618 to 0.5903 0.2760
log-logistic 0.3490 0.0991 to 0.6088 0.3350
log-normal 0.3413 0.0748 to 0.6195 0.3195
MPT survregbayes2()
Weibull 0.3558 0.0515 to 0.6524 0.3580
log-logistic 0.3584 0.0743 to 0.6713 0.3790
log-normal 0.3555 0.0665 to 0.6292 0.3535
Murray et al. (2016)
LRTP Splines 0.2233 -0.0352 to 0.4833 0.0841
? As of 22 July 2019, rstanarm development version, including the stan_surv() function, downloaded from the survival branch of the package available on
github at https://github.com/stan-dev/rstanarm/tree/feature/survival
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Figure 4. Convergence diagnostics in MCMC with default parameterization (1/2): from top to bottom, SemiCompRisks
package’s functions BayesSurv_HReg(..., model="Weibull"), BayesSurv_HReg(..., model=’PEM’), survHE package’s
functions fit.models(..., method="hmc", distr="exponential"), fit.models(..., method="hmc", distr="weibullPH"), rstanarm
package’s functions stan_surv(..., basehaz="exponential"), stan_surv(..., basehaz="weibull"), stan_surv(..., basehaz="ms"),
stan_surv(..., basehaz="bs"), Murray et al (2016)’s model.
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Figure 5. Convergence diagnostics in MCMC with default parameterization (2/2): dynsurv package function bayesCox(...,
model = "TimeIndep"), spBayesSurv package, from top to bottom, functions indeptCoxph(), survreg(..., survmodel="PH",
dist="weibull"), survreg(..., survmodel="PH", dist="loglogistic"), survreg(..., survmodel=’PH’, dist="lognormal"),
survreg2(..., survmodel="PH", dist="weibull"), survreg2(..., survmodel="PH", dist="loglogistic"), survreg(...,
survmodel="PH", dist="lognormal").
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5.2.2 Sensitivity analysis with optimized parameterizations
A sensitivity analysis was conducted with optimized MCMC parameterization to ensure convergence for the estimation of
posterior distributions (for functions using MCMC estimation).
We used 4 chains and set the number of iterations per chain and thinning interval in order to fulfill the following conditions
on MCMC convergence: burn-in representing half of the iterations, at least 1000 saved iterations per chain, effective sample
size to total number of iterations ratio (Ne f f : N ratio) greater than 0.5. Table 4 reports the optimized parametrizations which
were necessary to fullfill these criteria (total number of iterations per chain, including burn-in and before thinning, and thinning
interval). Figures 6 and 7 illustrate convergence for the different functions obtained with these optimized MCMC parameters.
Table 5 presents the estimates obtained on the data derived from the ALLOZITHRO trial, with optimized and homoge-
neous parameterization for functions using MCMC, and figure 8 illustrates the comparison between estimates with default
parameterization and those optimized (as relevant for functions using MCMC).
Table 4. Sensitivity analyses with optimized MCMC simulation: optimized MCMC parameterizations in the R packages for
Bayesian survival PH models (number of chains = 4 and burn-in to total number of iterations ratio = 0.5 for all), PEM:
piecewise exponential model.
Package/Method Total no. of iterations Thin
SemiCompRisks package
BayesSurv_HReg(, model=’Weibull’) 4.105 200
BayesSurv_HReg(, model=’PEM’) 2.105 100
Stan via survHE package
Parametric exponential 10000 5
Parametric Weibull 10000 5
Stan via rstanarm package
Parametric exponential 10000 5
Parametric Weibull 10000 5
M-splines 10000 5
B-splines 10000 5
dynsurv package
bayesCox() 10000 5
spBayesSurv package
indeptCoxph() 20000 10
survregbayes(..., survmodel="PH", dist="weibull") 10000 5
survregbayes(..., survmodel="PH", dist="loglogistic") 10000 5
survregbayes(..., survmodel="PH", dist="lognormal") 10000 5
survregbayes2(..., survmodel="PH", dist="weibull") 10000 5
survregbayes2(..., survmodel="PH", dist="loglogistic") 10000 5
survregbayes2(..., survmodel="PH", dist="lognormal") 10000 5
Murray et al (2016) 10000 5
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Table 5. ALLOZITHRO Trial: Sensitivity analysis for Bayesian functions using MCMC sampling, with optimized
parameterization. Estimates of the log hazard ratio (HR) of event (death or airflow decline) in the azithromycin group over
placebo according to the method. 95%CI refers to the credible intervals. PEM: piecewise exponential model; TBP: transformed
Bernstein polynomial; MPT: mixture of Polya trees
Estimation method Posterior logHR
Mean 95% CI Pr(HR > 1.5)
SemiCompRisks package
Parametric Weibull 0.3508 0.0905 to 0.6098 0.3475
PEM 0.3455 0.1622 to 0.5700 0.3100
Stan via survHE package
Parametric exponential 0.3505 0.0924 to 0.6144 0.3415
Parametric Weibull 0.3470 0.0860 to 0.6078 0.3233
Stan via rstanarm package?
Parametric exponential 0.3503 0.1011 to 0.6135 0.3313
Parametric Weibull 0.3550 0.0956 to 0.6356 0.3483
M-splines 0.2898 0.0282 to 0.5439 0.1823
B-splines 0.3569 0.0953 to 0.6286 0.3438
dynsurv package
PEM Gamma 0.2646 -0.0246 to 0.5530 0.1668
spBayesSurv package
PEM indeptCoxph() 0.3621 0.1004 to 0.6083 0.3733
TBP survregbayes()
dist="weibull" 0.3509 0.0875 to 0.6197 0.3402
dist="loglogistic" 0.3451 0.0867 to 0.6052 0.3290
dist="lognormal" 0.3434 0.0812 to 0.6016 0.3228
MPT survregbayes2()
dist="weibull" 0.3517 0.0765 to 0.6239 0.3522
dist="loglogistic" 0.3617 0.0906 to 0.6427 0.3852
dist="lognormal" 0.3542 0.0670 to 0.6350 0.3572
Murray et al. (2016)
LRTP Splines 0.2202 -0.0404 to 0.4745 0.0830
? As of 22 July 2019, rstanarm development version, including the stan_surv() function, downloaded from the survival branch of the package available on
github at https://github.com/stan-dev/rstanarm/tree/feature/survival
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Figure 6. Convergence diagnostics in sensitivity analysis for optimized MCMC: from top to bottom, SemiCompRisks
package’s functions BayesSurv_HReg(..., model="Weibull"), BayesSurv_HReg(..., model="PEM"), survHE package’s
functions fit.models(..., method="hmc", distr="exponential"), fit.models(..., method="hmc", distr="weibullPH"), dynsurv
package function bayesCox(..., model = "TimeIndep"), Murray et al (2016)’s model .
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Figure 7. Convergence diagnostics in sensitivity analysis for optimized MCMC: spBayesSurv package, from top to
bottom, functions indeptCoxph(), survreg(..., survmodel="PH", dist="weibull"), survreg(..., survmodel="PH",
dist="loglogistic"), survreg(..., survmodel="PH", dist="lognormal"), survreg2(..., survmodel="PH", dist="weibull"),
survreg2(..., survmodel="PH", dist="loglogistic"), survreg(..., survmodel="PH", dist="lognormal").
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Figure 8. ALLOZITHRO Trial: Forest plot of log(HR) posterior estimates by type of model and R function, using default
parameterization (black squares and segments) or optimized MCMC parameterization (surperimposed gray squares and
segments). Squares represent the posterior mean of log(HR) and segments the 95% credibility interval for Bayesian methods,
the maximum likelihood point estimate and 95% confidence interval for frequentist methods. ? function{package} or reference
publication.
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